NET SALES AS OF DECEMBER 31, 2017

Longjumeau, January 31, 2018

PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales as of December 31, 2017.

The PCAS Group had generated consolidated net sales of €218.3 million as of December 31, 2017, representing growth of +13.7% compared to the same period of the previous financial year.

In millions of euros  2017  2016 % change
       
 Net sales as of 31 December  218.3    192.0    13.7%
  Pharmaceutical Synthesis  148.9    130.0    14.6%
  Fine Specialty Chemicals  69.3    62.0    11.8%

Pharmaceutical Synthesis

The Pharmaceutical Synthesis business generated €148.9 million, up 14.6% on 2016, which was especially driven by the Exclusive activity.

Fine Specialty Chemicals

Net sales of Fine Specialty Chemicals totaled €69.3 million, up 11.8% on 2016, with growth in both Performance Additives and Advanced Specialty Chemicals, more particularly for the micro-electronics part.

  NEXT FINANCIAL DISCLOSURE:
2017 results, February 20, 2018

ABOUT PCAS 
PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. Boasting especially high standards, the company offers a growing range of proprietary products and solutions in leading-edge segments. PCAS generated net sales of €218.3 million in 2017 and employs close to 1 100 people in six countries.

To find out more about PCAS, visit: www.pcas.com

    
   
  
 

 

 

 

 

 

 


PCAS
 

 

 

 

 

 




NewCap
Vincent Touraille / Eric Moissenot
PCAS
Emmanuel Huynh / Louis-Victor Delouvrier
NewCap
Financial communication and Investor Relations
Tel. : +33 1 69 79 61 32
www.pcas.com

 
Tel. : +33 1 44 71 98 53
pcas@newcap.eu
PCAS_2017 net sales



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PCAS via Globenewswire